Genentech submitted the BLA for bevacizumab for the treatment of recurrent or metastatic cervical cancer.
Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for Avastin® (bevacizumab) plus chemotherapy for the treatment of women with persistent, recurrent or metastatic cervical cancer.
“This regulatory application for Avastin is important because chemotherapy is the only approved treatment for women with metastatic, recurrent or persistent cervical cancer,” said Sandra Horning, M.D., chief medical officer and head of Global Product Development. “Treatment with Avastin plus chemotherapy may help women with these conditions live longer than chemotherapy alone, and we look forward to working with the FDA on potentially making this medicine available to patients.”
Press release: http://on.mktw.net/1nEpO1l
Source: MarketWatch
NCCN Launches Pilot Project Aiming to Measure, Implement Health Equity in Cancer Care Practices
February 4th 2023Five leading academic cancer centers are assessing the feasibility of implementing the Health Equity Report Card pilot project as a tool that can both meaningfully and feasibly measure and report on equitable care practices.
Read More
Lymphoma Research Foundation CEO on Biden’s Cancer Moonshot, Financial Toxicity
February 3rd 2022On this episode of Managed Care Cast, we speak with Meghan Gutierrez, CEO of the Lymphoma Research Foundation, about financial toxicity, how the pandemic has affected patients’ financial needs when they have cancer, health care disparities and care gaps, and more.
Listen
Study Suggests MRI Is the Best Breast Cancer Screening Modality for Dense Breasts
February 1st 2023A review and meta-analysis published in the journal Radiology found MRI to be the most effective supplemental breast cancer screening method for women with dense breasts and negative mammogram results.
Read More
Interstitial Lung Abnormalities Impact OS in NSCLC Patients Receiving CRT, Adjuvant Durvalumab
January 19th 2023Pretreatment interstitial lung abnormalities were associated with worse overall and cause-specific survival in Japanese patients receiving chemoradiotherapy followed by adjuvant durvalumab for locally advanced non–small-cell lung cancer.
Read More
2 Clarke Drive
Cranbury, NJ 08512